The Novartis and Eli Lilly-backed developer of antifungal treatments, will seek to advance three of its candidates through clinical trials using the proceeds from the offering.
US-based biopharmaceutical company Viamet has filed for an initial public offering that could raise up to $75m.
Viamet develops treatments based around metalloenzymes, enzymes that contain a metal such as iron or zinc, to treat fungal diseases. It plans to use the funds to support progress of three of its drug candidates through Phase 1 or 2b clinical trials.
The company’s two largest shareholders are the corporate venturing units of pharmaceutical companies Novartis and Eli Lilly, which hold stakes…
